Having trouble accessing articles? Reset your cache.

Genzyme, sanofi-aventis deal

Genzyme rejected an unsolicited offer from sanofi-aventis to acquire the company for $69 per share in cash, or about $18.5 billion. The

Read the full 222 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE